Dr Zakharia on Real-World Outcomes With First-Line Axitinib Plus Pembrolizumab in RCC
November 11th 2023
Yousef Zakharia, MD, discusses the real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma based on International Metastatic RCC Database Consortium risk score.